Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers

被引：0

作者：

Sanborn, Rachel ^{[1
]}

Gabrail, Nashat ^{[2
]}

O'Hara, Mark ^{[3
]}

Bhardwaj, Nina ^{[4
]}

Gordon, Michael ^{[5
]}

Hauke, Ralph ^{[6
]}

Bordoni, Rodolfo ^{[7
]}

Khalil, Danny ^{[8
]}

Rawls, Tracey ^{[9
]}

Vitale, Laura ^{[9
]}

Gedrich, Richard ^{[9
]}

Hawthorne, Thomas ^{[10
]}

Keler, Tibor ^{[9
]}

Forsberg, Eirc ^{[9
]}

Thomas, Lawrence ^{[11
]}

Yellin, Michael ^{[9
]}

机构：

[1] Providence Canc Inst, Portland, OR USA

[2] Gabrail Canc Ctr, Canton, OH USA

[3] Hosp Univ PA, Philadelphia, PA USA

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] HonorHlth Res Inst, Scottsdale, AZ USA

[6] Nebraska Canc Specialists, Omaha, NE USA

[7] Northside Hosp Inc, Marietta, GA USA

[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[9] Celldex Therapeut Inc, Beacon, NY USA

[10] CelldexTherapeutics Inc, Hampton, NJ USA

[11] CelldexTherapeutics Inc, Needham, MA USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P827

引用

页数：2

共 19 条

[1] First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results
Sanborn, Rachel E.
Gabrail, Nashat Y.
Bhardwaj, Nina
Gordon, Michael S.
O'Hara, Mark
Khalil, Danny
Hawthorne, Thomas
Gedrich, Richard
Vitale, Laura
Rogalski, Mark
Li, Tianshu
Rawls, Tracey
Keler, Tibor
Yellin, Michael
CANCER RESEARCH, 2019, 79 (13)
[2] CDX1140-01, A PHASE 1 DOSE-ESCALATION/EXPANSION STUDY OF CDX-1140 ALONE (PART 1) AND IN COMBINATION WITH CDX-301 (PART 2) OR PEMBROLIZUMAB (PART 3)
Sanborn, Rachel
Hauke, Ralph
Gabrail, Nashat
O'Hara, Mark
Bhardwaj, Nina
Bordoni, Rodolfo
Gordon, Michael
Khalil, Danny
Abdelrahim, Maen
Marron, Thomas
Hawthorne, Thomas
Thomas, Lawrence
Rawls, Tracey
Rogalski, Mark
Alvarado, Diego
Vitale, Laura
Keler, Tibor
Yellin, Michael
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A246 - A246
[3] RESULTS FROM A PHASE 1 STUDY OF CDX-1140, A FULLY HUMAN ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (MAB), IN COMBINATION WITH PEMBROLIZUMAB
Sanborn, Rachel
Gabrail, Nashat
Carneiro, Benedito
O'Hara, Mark
Bordoni, Rodolfo
Gordon, Michael
Khalil, Danny
Hauke, Ralph
Taglienti, Cherie
Rogalski, Mark
Styles, Rachel
Alvarado, Diego
Maurer, Deena
Crew, Linda
Keler, Tibor
Yellin, Michael
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A624 - A624
[4] Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy
O'Hara, Mark H.
Wattenberg, Max
Garrido-Laguna, Ignacio
O'Reilly, Eileen M.
Yellin, Michael
Keler, Tibor
Gargano, Michele
Niles, Nick
Drees, Jeremy
Bose, Nandita
Beatty, Gregory L.
CANCER RESEARCH, 2024, 84 (17)
[5] A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Beatty, Gregory L.
Torigian, Drew A.
Chiorean, E. Gabriela
Saboury, Babak
Brothers, Alex
Alavi, Abass
Troxel, Andrea B.
Sun, Weijing
Teitelbaum, Ursina R.
Vonderheide, Robert H.
O'Dwyer, Peter J.
CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6286 - 6295
[6] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
Moreno, Victor
Perets, Ruth
Peretz-Yablonski, Tamar
Fourneau, Nele
Girgis, Suzette
Guo, Yue
Hellemans, Peter
Verona, Raluca
Pendas, Natalia
Xia, Qi
Geva, Ravit
Calvo, Emiliano
INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 93 - 104
[7] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
Victor Moreno
Ruth Perets
Tamar Peretz-Yablonski
Nele Fourneau
Suzette Girgis
Yue Guo
Peter Hellemans
Raluca Verona
Natalia Pendás
Qi Xia
Ravit Geva
Emiliano Calvo
Investigational New Drugs, 2023, 41 : 93 - 104
[8] A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors
Tran, Ben
Voskoboynik, Mark
Bendell, Johanna
Gutierrez, Martin
Lemech, Charlotte
Day, Daphne
Frentzas, Sophia
Garrido-Laguna, Ignacio
Standifer, Nathan
Wang, Fujun
Ferte, Charles
Wang, Yue
Das, Mayukh
Carneiro, Benedito A.
IMMUNOTHERAPY, 2024, 16 (11) : 759 - 774
[9] PHASE IB STUDY OF SELICRELUMAB (CD40 AGONIST) IN COMBINATION WITH ATEZOLIZUMAB (ANTI-PD-L1) IN PATIENTS WITH ADVANCED SOLID TUMORS
Barlesi, Fabrice
Lolkema, Martijn
Rohrberg, Kristoffer Staal
Hierro, Cinta
Marabelle, Aurelien
Razak, Albiruni Abdul
Teixeira, Luis
Boni, Valentina
Miller, Wilson H.
Aggarwal, Charu
Stern, Martin
Cirovic, Olivera
Cirovic, Olivera
Romagnoli, Barbara
Christen, Randolph
Dodia, Raksha
Smart, Kevin
Reis, Bernhard
Staedler, Nicolas
Watson, Carl
Steeghs, Neeltje
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A178 - A178
[10] Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
Machiels, Jean-Pascal
Gomez-Roca, Carlos
Michot, Jean-Marie
Zamarin, Dmitriy
Mitchell, Tara
Catala, Gaetan
Eberst, Lauriane
Jacob, Wolfgang
Jegg, Anna-Maria
Cannarile, Michael A.
Watson, Carl
Babitzki, Galina
Korski, Konstanty
Klaman, Irina
Teixeira, Priscila
Hoves, Sabine
Ries, Carola
Meneses-Lorente, Georgina
Michielin, Francesca
Christen, Randolph
Ruttinger, Dominik
Weisser, Martin
Delord, Jean-Pierre
Cassier, Philippe
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

← 1 2 →